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and costs of treating CVD complications in Swiss patients with
and without MS, using the National Cholesterol Education
Program Adults Treatment panel III (NCEP/ATP III) deﬁnition.
The 5-state Markov model utilized predictive regression equa-
tions and transition probabilities from the Framingham and
PROCAM epidemiological studies. Patient characteristics were
taken from the Lausanne Health Promotion Database which
consisted of 9401 patients aged 18 to 79 years. Patients in the
database were segmented according to their status of meeting the
criteria of having MS, CMRF, and their age. Direct medical costs
were accounted in 2005 Swiss Francs (CHF). Outcomes were
projected over a lifetime horizon and discounted at 5% per
annum. RESULTS: The presence of MS was projected to result
in decreased LE by 2.29 years (16.27 vs 13.98 years) compared
to individuals without the syndrome. The presence of MS was
consistently associated with lower LE in all patient age groups.
Direct medical costs of treating CVD complications in patients
with MS were CHF 4413 higher than patients without the 
syndrome (CHF 8382 vs. CHF 3969). The largest differences in
cost were estimated for patients aged above 75 years (CHF
11,744 vs. CHF 6707). CONCLUSIONS: On the basis of the
NCEP/ATP III deﬁnition, our modeling analysis concludes that
the presence of MS decreases LE (−2.29 years) and increases
CVD costs (CHF 4413) per patient in the Swiss setting. These
data suggest that the costs of future interventions targeted at 
the causes/management of MS could be offset by reduced CVD
costs.
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OBJECTIVES: Atrial ﬁbrillation (AF) is the most common
arrhythmic condition, with rising prevalence. AF increases stroke
and mortality rates. Ablation (percutaneous and surgical) pro-
vides a more permanent solution to AF compared to drugs and
reduces stroke and mortality rates. Performing surgical ablation
(SA) concomitantly to cardiac surgery (CABG or valvular repair)
only lengthens surgery with maximum 30 min without increas-
ing complication rates. The aim of this study was to assess the
cost-effectiveness of concomitant SA for permanent AF, with the
UK as a case country. METHODS: A Markov model, compar-
ing no ablation during surgery (NSA) with concomitant SA for
AF, was developed in TreeAge. The initial cardiac surgery (with
or without SA) can result in short-term complications (mortal-
ity, stroke, bleeding leading to re-surgery, and pacemaker
implantation) or not. 4 different health states were deﬁned: sinus
rhythm without complications, AF without complications,
history of stroke and death. Every 3 months (for a total of 5
years) the patient had a risk to die or to have a stroke or an AF
recurrence. Clinical data were derived from published data (3-
month free of AF after SA 81% vs. 23% for NSA). Direct costs
from the NHS (2006) perspective were used. The cost of SA was
assumed to be GBP2500. Utility data (TTO) were obtained from
published data and from the Euro Heart Survey (utility perma-
nent AF = 0.78). Costs and effects were discounted at 3.5%
annually. RESULTS: Over the 5-year modeling period SA
resulted in 0.427 QALY gained (3.079 QALY vs. 2.652 QALY)
for an additional cost of GBP2054 (GBP4567 vs. GBP2513). The
incremental cost-effectiveness ratio (ICER) was GBP4810/
QALYG. Doubling the modelling period decreased ICER with
50%. Increasing utility of AF to 0.97 increased ICER to
GBP19,106/QALYG. CONCLUSIONS: Compared to no abla-
tion, concomitant SA is a cost-effective treatment for AF in the
UK.
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Hypertension is a common condition leading to increased risk of
excess mortality and morbidity from cardiovascular events (AMI
and stroke). Furthermore, it is known that blood pressure reduc-
tion of 2–5 mmHg has an impact on the patients risk for car-
diovascular events and mortality. In a double blinded RCT
irbesartan 300 mg reduced systolic blood pressure by 16.4
mmHg while losartan 100 mg reduced blood pressure by 11.3
mmHg. P value was signiﬁcant (p < 0.05). OBJECTIVE: To
assess the cost-effectiveness of long-term treatment of hyperten-
sion with irbesartan vs. losartan in a Danish setting.
METHODS: A Markov model was developed using the SCORE
risk function to predict cardiovascular events depending on
blood pressure level and other risk factors. The effect of irbe-
sartan and losartan was taken from a RCT study with direct
comparison (the Kassler-Taub study). In this study, irbesartan
was also compared to no treatment. In the model, lifelong treat-
ment was evaluated with either early intervention, when hyper-
tension occurs (age 55), or late intervention after the occurrence
of the ﬁrst cardiovascular event. Health outcomes were number
of cardiovascular events, life years and QALYs gained. Danish
costs and epidemiological data were applied. RESULTS: Irbe-
sartan was shown to be cost-saving vs. losartan (−€5.950/LYG).
Compared to placebo, early intervention was shown to be more
cost-effective relative to late intervention. CONCLUSIONS:
Long-term treatment of hypertension with irbesartan can be
cost-saving compared to treatment with losartan.
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OBJECTIVES: Bivalirudin, a selective thrombin inhibitor, has
been approved as an alternative treatment to the use of heparin
in patients undergoing percutaneous coronary intervention
(PCI). The objective is to evaluate the efﬁciency measured as the
health care costs savings, due to the replacement of the current
heparin plus glycoprotein IIb/IIIa inhibition (abciximab) by
bivalirudin in patients undergoing PCI. METHODS: Regarding
the incidence of ischaemic events, it has been proved the equiv-
alence between heparin plus inhibitors of glycoprotein and
bivalirudin, noticing a smaller rate of bleeding complications in
the group treated with bivalirudin (REPLACE 2). Based on this
ﬁnding a cost minimization analysis (CMA) has been carried out
focusing on the differential costs when using both treatments:
the drug cost, the cost of major bleeding management (bleeding
at puncture point and digestive bleeding). Two experts in inter-
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ventionist cardiology veriﬁed the cost of the management of
bleeding complications. RESULTS: The management cost of 100
patients subjected to PCI and treated with heparin plus abcix-
imab is €89,023.67, and €57,703.76 if treated with bivalirudin,
which results in an incremental cost of €313.2 per patientk. In
the group of patients subjected to PCI, with the bivalirudin
option, and without modifying the hospital budget, 54 out of
100 patients more could be treated with a similar level of pro-
tection and a smaller bleeding risk. CONCLUSIONS: Bivaliru-
dina should be considered as the anticoagulant ﬁrst option in
those patients undergoing PCI and that are currently receving
heparin plus glycoprotein IIb/IIIa inhibition.
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OBJECTIVE: to study direct medical costs for treatment of mild
to moderate hypertension in patients with type II diabetes in the
perspective of the Italian National Health care System (NHS).
METHODS: this was a randomized parallel group clinical study;
after a 2 weeks run-in period, eligible patients DBP≤(90 < 140)
were randomized to treatment with delapril (D) 30≥110; SBP
mg/die, ramipril 2.5 mg/die (R) or valsartan (V) 80 mg/die. After
6 weeks of active treatment, uncontrolled patients were switched
to combination therapies: D + manidipine 10 mg (D + M); R +
hydrochlorothiazide 12.5 mg (R + HCTZ); V + hydrochloroth-
iazide 12.5 mg (V + HCTZ), whilst patients with satisfactory BP
levels were kept on monotherapy. The economic analysis was run
in the perspective of the Italian NHS; only direct medical costs
were considered, including study drugs, unscheduled medical
visits and tests, hypoglycaemic drugs and drugs used to treat
adverse events. Year 2006 market prices and NHS tariffs were
applied; for D + M we considered a target price of €23.24 for
28 tablets pack (not marketed yet in Italy). RESULTS: 425
patients were included (ITT), of which 139 were treated with
D/D + M, 145 with R/R + HCTZ and 141 with V/V + HCTZ.
No statistically signiﬁcant differences were found among the 3
study groups, on the primary efﬁcacy variable of DBP, on the
number of patients requiring combination therapy and on sec-
ondary efﬁcacy parameters. Therefore the economic analysis was
a cost-minimisation analysis with costs normalised at 1 year to
account for slightly different lengths of follow-up. Average costs
per patient/year for D/D + M vs. R/R + HCTZ and V/V + HCTZ
was €643 vs. €636 vs. €759 respectively. CONCLUSION:
the study demonstrates that, despite similar BP control, there are
differences in the NHS annual cost, between patients treated
with ACE inhibitors (with/without diuretic or CCBs) and 
those treated with a speciﬁc angiotensin II receptor antagonist
(with/without diuretic).
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OBJECTIVES: Multiple publications have reported the positive
effects of rehabilitation in cardiac patients, also post-
percutaneous coronary intervention (PCI). However, the cost
remains an important hurdle for the payer to fully support
cardiac rehabilitation. The aim of this study was to, retrospec-
tively, assess the clinical outcomes and associated costs of
patients who underwent PCI with or without rehabilitation in a
Belgian hospital. METHODS: The patient ﬁles of 213 consecu-
tive patients who underwent a PCI between February 1998 and
December 1999 were analysed in January 2006. 133 patients
started a 3-month rehabilitation program, 80 did not. All major
adverse cardiac events (including angina, MI, re-PCI or CABG,
other hospitalisation, cardiovascular and other death) were
reported. All the events that occurred over the study period were
costed using unit cost data from the payer’s perspective obtained
from ofﬁcial sources. The cost of one rehabilitation session is
€23.25. RESULTS: The average follow-up period was 4.8 years.
The average number of rehabilitation sessions performed was
42.1. Less (not signiﬁcantly) patients in the rehabilitation group
were re-hospitalised (43% vs. 56%; p = 0.065) and the number
of re-hospitalisations (more than 1 per patient) for angina (45%
vs. 75%; p < 0.01) and revascularizations (8% vs. 18%; p <
0.05) was signiﬁcantly reduced. Mortality was not different
between the treatment groups. The average cost per patient over
the 4.8 years study period was €4862 (st.err €529) in the reha-
bilitation and €5498 (st.err €741) in the no rehabilitation group
(p = NS). Patients in the rehabilitation group were younger (p <
0.01) but logistic regression analysis (univariate and multivari-
ate) showed no signiﬁcant effect of age on angina and revascu-
larization incidence in the total population. CONCLUSIONS:
The cost of cardiac rehabilitation is more than totally offset by
the signiﬁcant reduction in cardiac events. Based on this study a
cardiac rehabilitation program should be installed in all patients
undergoing PCI.
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OBJECTIVES: The Joint British Societies (JBS) 2005 guideline
on prevention of cardiovascular disease (CVD) advocates pre-
vention in people with established CVD, with diabetes and with
CVD risk ≥20% over 10 years. This study was designed to estab-
lish the number of patients eligible for statin treatment in Scot-
land under these new guidelines, compared to those previously
eligible under the National Service Framework (NSF) for CHD
2000, and estimate the budget impact of treating these additional
patients to the JBS 2 optimal total cholesterol (TC) target of 
<4.0 mmol/L. METHODS: Data from the Scottish Health Survey
2003 (mean baseline TC, incidence of CVD and diabetes) were
combined with predicted coronary heart disease (CHD) risk esti-
mates and population statistics in an Excel-based model to 
estimate number of eligible patients. Efﬁcacy data from the
STELLAR (Statin Therapies for Elevated Lipid Levels compared
Across doses to Rosuvastatin) trial and pack costs from standard
sources were used to determine percentage of patients reaching
the speciﬁed TC target and annual treatment costs for alterna-
tive strategies comprising simvastatin 40 mg followed by either
atorvastatin (20 mg, 40 mg and 80 mg) or rosuvastatin (10 mg,
20 mg and 40 mg). RESULTS: The results using JBS 2, showed
21.3% of the adult population in Scotland is eligible for statin
treatment: a total of 881,402 people. Using the NSF, only 12.4%
or 513,600 people were eligible, this is an increase of 367,802
(8.9%). The cost of treating these additional patients with the
